Longevity Health Holdings Inc.(XAGE)Earnings, Financials & Key Ratios
XAGE•NASDAQ
Price updated Jun 19, 2026
AboutLongevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.Show more
- Revenue$50K
- EBITDA-$5M+5.7%
- Net Income-$10M+32.9%
- EPS (Diluted)-0.50+32.4%
- Gross Margin87.37%
- EBITDA Margin-9541.79%
- Operating Margin-9933.82%
- Net Margin-20605.47%
- ROE-103.49%-65.8%
XAGE Key Insights
Longevity Health Holdings Inc. (XAGE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XAGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XAGE Price & Volume
Longevity Health Holdings Inc. (XAGE) stock price & volume — 10-year historical chart
Loading chart...
XAGE Growth Metrics
Longevity Health Holdings Inc. (XAGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM139.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-187.75%
Return on Capital
10 Years-49.97%
5 Years-49.97%
3 Years-49.97%
Last Year-47.51%
XAGE Peer Comparison
Longevity Health Holdings Inc. (XAGE) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 WELL | 144.78B | 206.65 | 148.67 | 35.82% | 12.31% | 3.49% | 0.49 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 TALK | 872.74M | 5.21 | 130.25 | 22% | 0.49% | 1.03% | ||
 AMWL | 140.85M | 8.43 | -1.41 | -1.98% | -48.16% | -33.48% | 0.02 | |
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 | |
 OPRX | 93.45M | 4.98 | 18.44 | 18.78% | 6.37% | 5.47% | 0.20 |
Compare XAGE vs Peers
Longevity Health Holdings Inc. (XAGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XAGE Income Statement
Longevity Health Holdings Inc. (XAGE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 50.32K | 1.46M |
Revenue Growth % | - | - | - | - | 139.43% |
Cost of Goods Sold | 0 | 242.56K | 124.79K | 6.36K | 661.19K |
COGS % of Revenue | - | - | - | 12.63% | - |
Gross Profit | 0▲ 0% | -242.56K▲ 0% | -124.79K▲ 48.6% | 43.96K▲ 135.2% | 796.12K▲ 0% |
Gross Margin % | - | - | - | 87.37% | 54.63% |
Gross Profit Growth % | - | - | 48.55% | 135.23% | - |
Operating Expenses | 1.94M | 5.27M | 5.09M | 5.04M | 6.64M |
OpEx % of Revenue | - | - | - | 10021.18% | - |
Selling, General & Admin | 863.33K | 3.22M | 2.6M | 3.9M | 5.76M |
SG&A % of Revenue | - | - | - | 7759.97% | - |
Research & Development | 982.84K | 2.2M | 2.5M | 1.05M | 842.53K |
R&D % of Revenue | - | - | - | 2095.29% | - |
Other Operating Expenses | 94.16K | -148.26K | 0 | 83.49K | 33.77K |
Operating Income | -467.43K▲ 0% | -5.51M▼ 1078.3% | -5.22M▲ 5.3% | -5M▲ 4.2% | -5.84M▲ 0% |
Operating Margin % | - | - | - | -9933.82% | -400.96% |
Operating Income Growth % | - | -1078.28% | 5.27% | 4.19% | - |
EBITDA | -225.31K | -5.27M | -5.09M | -4.8M | -5.65M |
EBITDA Margin % | - | - | - | -9541.79% | -387.64% |
EBITDA Growth % | - | -2236.85% | 3.28% | 5.72% | -153.76% |
D&A (Non-Cash Add-back) | 242.12K | 242.56K | 124.79K | 197.26K | 194.12K |
EBIT | -329.38K | -5.3M | -15.32M | -10.7M | -5.91M |
Net Interest Income | -2.49M | -1.5M | -889.32K | -49.02K | -20.13K |
Interest Income | 8.09K | 2.25M | 0 | 0 | 0 |
Interest Expense | 2.5M | 3.75M | 889.32K | 49.02K | 20.13K |
Other Income/Expense | 138.05K | -3.54M | -10.99M | -5.75M | 9.63K |
Pretax Income | -329.38K▲ 0% | -9.05M▼ 2648.0% | -16.21M▼ 79.0% | -10.75M▲ 33.7% | -5.83M▲ 0% |
Pretax Margin % | - | - | - | -21359.64% | -400.3% |
Income Tax | 0 | 0 | 0 | -97.28K | -97.28K |
Effective Tax Rate % | 0% | 0% | 0% | 0.91% | 1.67% |
Net Income | -6.48M▲ 0% | -9.05M▼ 39.7% | -15.45M▼ 70.6% | -10.37M▲ 32.9% | -5.74M▲ 0% |
Net Margin % | - | - | - | -20605.47% | -393.63% |
Net Income Growth % | - | -39.7% | -70.64% | 32.87% | 8.9% |
Net Income (Continuing) | -329.38K | -9.05M | -16.21M | -10.65M | -5.74M |
Discontinued Operations | 0 | 0 | 760.16K | 282.2K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -0.50▼ 4487.2% | -0.74▼ 48.0% | -0.50▲ 32.4% | -3.33▲ 0% |
EPS Growth % | - | -4487.16% | -48% | 32.43% | -187.75% |
EPS (Basic) | -0.01 | -0.50 | -0.74 | -0.50 | - |
Diluted Shares Outstanding | 19.77M | 19.77M | 20.77M | 20.91M | 1.72M |
Basic Shares Outstanding | 19.77M | 19.77M | 20.77M | 20.91M | 1.72M |
Dividend Payout Ratio | - | - | - | - | - |
XAGE Balance Sheet
Longevity Health Holdings Inc. (XAGE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 178.7K | 605.54K | 62.9M | 955.55K | 2.84M |
Cash & Short-Term Investments | 774.19K | 128.15K | 2.91M | 157.14K | 1.11M |
Cash Only | 774.19K | 128.15K | 2.91M | 157.14K | 1.11M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 204.56K | 305.93K | 46.52K |
Days Sales Outstanding | - | - | - | 2.22K | 69.21 |
Inventory | 0 | 0 | 0 | 108.7K | 1.01M |
Days Inventory Outstanding | - | - | - | 6.24K | 507.09 |
Other Current Assets | -794.47K | 422.32K | 59.02M | 86.31K | 301.84K |
Total Non-Current Assets | 1.38M | 1.14M | 1.05M | 518.43K | 455.03K |
Property, Plant & Equipment | 1.35M | 1.11M | 1.02M | 498.79K | 438.8K |
Fixed Asset Turnover | - | - | - | 0.10x | 3.03x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 33.22K | 28.7K | 24.19K | 19.64K | 16.23K |
Long-Term Investments | 154.45M | 156.69M | 0 | 0 | 0 |
Other Non-Current Assets | -154.45M | -156.69M | 0 | 0 | 0 |
Total Assets | 1.56M▲ 0% | 1.75M▲ 12.3% | 63.95M▲ 3557.3% | 1.47M▼ 97.7% | 3.3M▲ 0% |
Asset Turnover | - | - | - | 0.03x | 0.49x |
Asset Growth % | - | 12.29% | 3557.25% | -97.7% | -134.71% |
Total Current Liabilities | 15.8M | 7.3M | 38.5M | 5.88M | 6.84M |
Accounts Payable | 871.31K | 2.14M | 4.42M | 4.06M | 4.17M |
Days Payables Outstanding | - | 3.22K | 12.92K | 233K | 2.4K |
Short-Term Debt | 8.6M | 2.78M | 1.29M | 241.16K | 286.06K |
Deferred Revenue (Current) | 2.37M | 1.39M | 0 | 0 | 0 |
Other Current Liabilities | 1.96M | 349.26K | 31.35M | 0 | 116.81K |
Current Ratio | 0.01x | 0.08x | 1.63x | 0.16x | 0.42x |
Quick Ratio | 0.01x | 0.08x | 1.63x | 0.14x | 0.27x |
Cash Conversion Cycle | - | - | - | -224.54K | -1.83K |
Total Non-Current Liabilities | 15.33M | 32.24M | 697.72K | 309.94K | 435.35K |
Long-Term Debt | 922 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 961.91K | 827.73K | 697.72K | 309.94K | 1.1M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14.37M | 31.42M | 0 | 0 | 196.09K |
Total Liabilities | 31.13M | 39.54M | 39.2M | 6.19M | 7.28M |
Total Debt | 9.69M | 3.74M | 2.14M | 638.99K | 618.63K |
Net Debt | 8.91M | 3.61M | -776.01K | 481.85K | -490.6K |
Debt / Equity | - | - | 0.09x | - | -0.16x |
Debt / EBITDA | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | 0.09x |
Interest Coverage | -0.19x | -1.47x | -5.87x | -101.98x | -293.50x |
Total Equity | -29.58M▲ 0% | -37.79M▼ 27.8% | 24.75M▲ 165.5% | -4.71M▼ 119.0% | -3.98M▲ 0% |
Equity Growth % | - | -27.77% | 165.49% | -119.04% | -462.79% |
Book Value per Share | -1.50 | -1.91 | 1.19 | -0.23 | -2.31 |
Total Shareholders' Equity | -29.58M | -37.79M | 24.75M | -4.71M | -3.98M |
Common Stock | 36.92K | 14.53K | 2.31K | 2.09K | 178 |
Retained Earnings | -32.77M | -42.38M | -58.5M | -68.87M | -73.69M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -31.42M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
XAGE Cash Flow Statement
Longevity Health Holdings Inc. (XAGE) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -1.18M | -3.81M | -8.35M | -4.39M | -3.79M |
Operating CF Margin % | - | - | - | -8722.42% | - |
Operating CF Growth % | - | -223.83% | -119.06% | 47.43% | 129.79% |
Net Income | -6.48M | -9.05M | -15.45M | -11.8M | -5.74M |
Depreciation & Amortization | 242.12K | 242.56K | 124.79K | 197.26K | 215.5K |
Stock-Based Compensation | 246.8K | 636.37K | 667.68K | 827.04K | 575.33K |
Deferred Taxes | 2.52M | -194.59K | 0 | 0 | 0 |
Other Non-Cash Items | 1.35M | 2.22M | 9.73M | 5.72M | -275.22K |
Working Capital Changes | 952.69K | 2.34M | -3.42M | 669.49K | 1.33M |
Change in Receivables | 0 | 0 | -204.56K | -101.38K | -52.17K |
Change in Inventory | 0 | 0 | 204.56K | -108.7K | 323.58K |
Change in Payables | 80.32K | 1.06M | -449.87K | -359.14K | -353.17K |
Cash from Investing | -7.27K | -7.16K | -30.47K | -748.8K | -164.22K |
Capital Expenditures | -7.27K | -7.16K | -30.47K | 0 | -14.22K |
CapEx % of Revenue | - | - | - | - | 0.98% |
Acquisitions | 0 | 0 | 0 | -748.8K | -150K |
Investments | - | - | - | - | - |
Other Investing | 154.44M | 0 | 0 | 0 | 0 |
Cash from Financing | 1.2M | 3.93M | 11.16M | 2.38M | 3.93M |
Debt Issued (Net) | 1.12M | 2.75M | -3.2M | -218.49K | -466.39K |
Equity Issued (Net) | 3.19K | 1000K | 41.07K | 1000K | 3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -2.29K | 0 | 0 | 0 |
Other Financing | 67.82K | 125.88K | 14.32M | -86.31K | -86.31K |
Net Change in Cash | 11.21K▲ 0% | 115.79K▲ 932.7% | 2.78M▲ 2304.7% | -2.76M▼ 199.0% | -28.1K▲ 0% |
Free Cash Flow | -1.18M▲ 0% | -3.44M▼ 190.2% | -8.38M▼ 143.9% | -4.39M▲ 47.6% | -3.81M▲ 0% |
FCF Margin % | - | - | - | -8722.42% | -261.39% |
FCF Growth % | - | -190.17% | -143.86% | 47.62% | 43.66% |
FCF per Share | -0.06 | -0.17 | -0.40 | -0.21 | -2.21 |
FCF Conversion (FCF/Net Income) | 0.18x | 0.42x | 0.54x | 0.42x | 0.66x |
Interest Paid | 0 | 0 | 283.53K | 29.47K | 15.07K |
Taxes Paid | 0 | 0 | 750K | 0 | 0 |
XAGE Key Ratios
Longevity Health Holdings Inc. (XAGE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | - | -62.41% | -103.49% | 141.35% |
Return on Invested Capital (ROIC) | - | - | -37.98% | 99.21% |
Gross Margin | - | - | 87.37% | 54.63% |
Net Margin | - | - | -20605.47% | -393.63% |
Debt / Equity | - | 0.09x | - | -0.16x |
Interest Coverage | -1.47x | -5.87x | -101.98x | -293.50x |
FCF Conversion | 0.42x | 0.54x | 0.42x | 0.66x |
Revenue Growth | - | - | - | 139.43% |
Related:XAGE Dividend History·XAGE Revenue History·XAGE Price History·XAGE P/E History·XAGE Financial Ratios·XAGE Institutional Holders
XAGE Frequently Asked Questions
Longevity Health Holdings Inc. (XAGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Longevity Health Holdings Inc. (XAGE) reported $1.5M in revenue for fiscal year 2024.
Longevity Health Holdings Inc. (XAGE) grew revenue by 0.0% over the past year. Growth has been modest.
Longevity Health Holdings Inc. (XAGE) reported a net loss of $5.7M for fiscal year 2024.
Dividend & Returns
Longevity Health Holdings Inc. (XAGE) has a return on equity (ROE) of -103.5%. Negative ROE indicates the company is unprofitable.
Longevity Health Holdings Inc. (XAGE) had negative free cash flow of $3.8M in fiscal year 2024, likely due to heavy capital investments.